Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Stamm

Showing results (141-150 of 155) with videos related to

Pageof 16
Sort By:
Journal of Neurotrauma|July 23, 2015
Age at First Exposure to Football Is Associated with Altered Corpus Callosum White Matter Microstructure in Former Professional Football PlayersJulie M Stamm, Inga K Koerte, Marc Muehlmann, et al.
The Lancet. Gastroenterology & Hepatology|June 4, 2018
Deferred treatment with sofosbuvir-velpatasvir-voxilaprevir for patients with chronic hepatitis C virus who were previously treated with an NS5A inhibitor: an open-label substudy of POLARIS-1Marc Bourlière, Stuart C Gordon, Eugene R Schiff, et al.
Gastroenterology|August 4, 2016
Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Genotype 1 Hepatitis C Virus Infection in an Open-Label, Phase 2 TrialEric Lawitz, Nancy Reau, Federico Hinestrosa, et al.
Neurology|August 23, 2013
Clinical presentation of chronic traumatic encephalopathyRobert A Stern, Daniel H Daneshvar, Christine M Baugh, et al.
Gastroenterology|July 1, 2018
Efficacy of Sofosbuvir and Velpatasvir, With and Without Ribavirin, in Patients With Hepatitis C Virus Genotype 3 Infection and CirrhosisRafael Esteban, Juan A Pineda, Jose Luis Calleja, et al.
Translational Psychiatry|September 20, 2017
Age of first exposure to American football and long-term neuropsychiatric and cognitive outcomesM L Alosco, A B Kasimis, J M Stamm, et al.
Physical Review Letters|February 1, 2008
Fill-tube-induced mass perturbations on x-ray-driven, ignition-scale, inertial-confinement-fusion capsule shells and the implications for ignition experimentsG R Bennett, M C Herrmann, M J Edwards, et al.
Gastroenterology|August 4, 2016
Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Hepatitis C Virus Genotype 2, 3, 4, or 6 Infections in an Open-Label, Phase 2 TrialEdward J Gane, Kris V Kowdley, David Pound, et al.
The New England Journal of Medicine|July 22, 2015
Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1Susanna Naggie, Curtis Cooper, Michael Saag, et al.
JHEP Reports : Innovation in Hepatology|March 21, 2024
Long-term open-label vebicorvir for chronic HBV infection: Safety and off-treatment responsesMan-Fung Yuen, Scott Fung, Xiaoli Ma, et al.
Pageof 16

Showing results (141-150 of 155) with videos related to

Sort By:
Pageof 16
Journal of Neurotrauma|July 23, 2015
Age at First Exposure to Football Is Associated with Altered Corpus Callosum White Matter Microstructure in Former Professional Football PlayersJulie M Stamm, Inga K Koerte, Marc Muehlmann, et al.
The Lancet. Gastroenterology & Hepatology|June 4, 2018
Deferred treatment with sofosbuvir-velpatasvir-voxilaprevir for patients with chronic hepatitis C virus who were previously treated with an NS5A inhibitor: an open-label substudy of POLARIS-1Marc Bourlière, Stuart C Gordon, Eugene R Schiff, et al.
Gastroenterology|August 4, 2016
Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Genotype 1 Hepatitis C Virus Infection in an Open-Label, Phase 2 TrialEric Lawitz, Nancy Reau, Federico Hinestrosa, et al.
Neurology|August 23, 2013
Clinical presentation of chronic traumatic encephalopathyRobert A Stern, Daniel H Daneshvar, Christine M Baugh, et al.
Gastroenterology|July 1, 2018
Efficacy of Sofosbuvir and Velpatasvir, With and Without Ribavirin, in Patients With Hepatitis C Virus Genotype 3 Infection and CirrhosisRafael Esteban, Juan A Pineda, Jose Luis Calleja, et al.
Translational Psychiatry|September 20, 2017
Age of first exposure to American football and long-term neuropsychiatric and cognitive outcomesM L Alosco, A B Kasimis, J M Stamm, et al.
Physical Review Letters|February 1, 2008
Fill-tube-induced mass perturbations on x-ray-driven, ignition-scale, inertial-confinement-fusion capsule shells and the implications for ignition experimentsG R Bennett, M C Herrmann, M J Edwards, et al.
Gastroenterology|August 4, 2016
Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Hepatitis C Virus Genotype 2, 3, 4, or 6 Infections in an Open-Label, Phase 2 TrialEdward J Gane, Kris V Kowdley, David Pound, et al.
The New England Journal of Medicine|July 22, 2015
Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1Susanna Naggie, Curtis Cooper, Michael Saag, et al.
JHEP Reports : Innovation in Hepatology|March 21, 2024
Long-term open-label vebicorvir for chronic HBV infection: Safety and off-treatment responsesMan-Fung Yuen, Scott Fung, Xiaoli Ma, et al.
Pageof 16